The clinical management of Coronary Artery Disease (CAD) and the prevention of Acute Coronary Syndromes (ACS) require knowledge of the underlying atherosclerotic plaque pathobiology. Current intravascular standalone imaging techniques are limited in their ability to evaluate processes that lead to plaque progression and sudden changes in plaque structure (e.g. rupture or erosion) conducive to ACS in humans. Hybrid intravascular imaging systems hold premises for more comprehensive evaluation of plaque pathobiology in patients and are urgently needed.
The goal of the Marcu Lab is to address this need through the development of an intravascular imaging approach capable of simultaneous assessment of changes in plaque biochemical composition and morphology associated with critical pathobiological processes in patients. Time-resolved measurements of endogenous fluorophores present key advantages compared to intensity-based measurements, such as independence of contrast from the probe to wall distance or residual blood absorption, and do not require the lengthy approval required for exogenous contrast agents thus facilitating future translational work.
Over the years, we have studied how the autofluorescence signature of atherosclerotic lesions relates to their composition and how FLIm could be used to yield greater insight into the interplay of biochemical-morphological features that have a key role in plaque progression, destabilization, and/or remodeling.